201 HASKINS WAY, SOUTH SAN FRANCISCO, CA
Reports Q4 and Full Year 2025 Business and Financial Results
Smital Shah Appointed Chief Financial and Business Officer
Other Events
Bylaw Amendments Approved by Lyell Immunopharma Board on December 3, 2025
Reports Business Highlights and Financial Results for the Third Quarter 2025
Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Lynn Seely Appointed Interim Principal Financial Officer at Lyell Immunopharma
Changes in Board, Management or Compensation
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload